enGene Therapeutics growth metrics data for the quarter ended Jul 2026. These growth metrics cover 14 quarters of results from Apr 2023 through Jul 2026, standardized by Business Quant from the company’s SEC filings.
| Growth Metrics | Apr2023 | Jul2023 | Oct2023 | Jan2024 | Apr2024 | Jul2024 | Oct2024 | Jan2025 | Apr2025 | Jul2025 | Oct2025 | Jan2026 | Apr2026 | Jul2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth Ratios | ||||||||||||||
| Interest Coverage Ratio Growth (1y)Interest Cover Growth (1y) | -385.29% | -490.80% | -415.03% | -156.27% | -84.95% | -55.41% | -77.04% | -128.00% | -20.38% | -16.12% | -2.13% | |||
| Interest Coverage Ratio Growth (3y)Interest Cover Growth (3y) | -121.07% | -120.10% | -110.39% | |||||||||||
| Interest Coverage Ratio (QoQ)Interest Cover (QoQ) | -2.07% | -7.66% | -107.93% | -112.39% | -24.26% | 6.15% | -3.46% | -53.28% | -4.42% | -6.91% | -33.24% | 19.07% | -0.72% | 5.97% |
| Return on Assets [ROA] Growth (1y)ROA Growth (1y) | 9,131.00 | 3,263.00 | 829.00 | -3116.00 | -2071.00 | -1044.00 | -677.00 | |||||||
| Return on Assets [ROA] (QoQ)ROA (QoQ) | 5,290.00 | 1,626.00 | 2,620.00 | -405.00 | -578.00 | -808.00 | -1325.00 | 640.00 | 448.00 | -440.00 | ||||
| Return on Capital Employed [ROCE] Growth (1y)ROCE Growth (1y) | 1,130.00 | -878.00 | -2138.00 | -3841.00 | -2280.00 | -1002.00 | -756.00 | |||||||
| Return on Capital Employed [ROCE] (QoQ)ROCE (QoQ) | 1,339.00 | 374.00 | -117.00 | -465.00 | -669.00 | -887.00 | -1820.00 | 1,096.00 | 608.00 | -641.00 | ||||
| Return on Equity [ROE] Growth (1y)ROE Growth (1y) | -944.00 | |||||||||||||
| Return on Equity [ROE] (QoQ)ROE (QoQ) | -644.00 | |||||||||||||
| Return on Invested Capital [ROIC] Growth (1y)ROIC Growth (1y) | 16,133.00 | 1,105.00 | -812.00 | -2155.00 | -2387.00 | -1144.00 | -819.00 | |||||||
| Return on Invested Capital [ROIC] (QoQ)ROIC (QoQ) | 14,550.00 | 1,298.00 | 424.00 | -138.00 | -479.00 | -619.00 | -919.00 | 624.00 | -570.00 |